Company / Free Cash Flow
Exelixis Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$875.8M
FY2025
5-year range
$178.6M / $875.8M
FY2021-FY2025
Trend
+30.4%
vs FY2024
Sector context
#18 of 194
Health Care
What the data says
Among 194 Health Care companies, Exelixis is in the top 9% for free cash flow. Free Cash Flow has increased for 3 consecutive years, from $179M in FY2022 to $876M in FY2025.
Based on SEC 10-K filings.
$876M in FY2025 with a 5-year CAGR of +37.4%. Top quartile in the Health Care sector.
Improved from $293M to $876M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +69.9%
- 5-Year CAGR
- +37.4%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 194This company $875.8M Sector average $470.8M
▼
+86.0% above sector average
Key checks
Key Insights
- Exelixis's free cash flow has grown for 3 consecutive years.
- 5-year CAGR of +37.4%, indicating consistent growth.
- In FY2025, free cash flow increased 30.4% year-over-year.
- Ranks #18 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.33 (safe zone, above 2.9 threshold)
- Strong profit margin: 29.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 31.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $875.8M | +30.4% |
| FY2024 | $671.5M | +129.3% |
| FY2023 | $292.9M | +63.9% |
| FY2022 | $178.6M | -65.3% |
| FY2021 | $514.1M | +187.8% |
| FY2020 | $178.6M | -65.3% |
| FY2019 | $514.1M | +146.3% |
| FY2018 | $208.7M | +44.5% |
| FY2017 | $144.5M | -30.8% |
| FY2016 | $208.7M | +246.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026